36.8 F
New York
Thursday, January 21, 2021

Looking Into the Buzz Propelling Mind Medicine Inc (OTCMKTS:MMEDF)

Must read

CytoDyn Inc (OTCMKTS:CYDY) Hits 4-Month High As Covid-19 Fear Grows

The coronavirus pandemic unleashed chaos all over the world and also in the markets, however, some biotech companies working on treatments for...

Alpine 4 Technologies Ltd (OTCMKTS:ALPP) Hits New High as Market Share Grows

Monday was not a particularly great time in the markets owing to renewed fears about COVID 19, but there were some stocks...

Grayscale Ethereum Trust (ETH) (OTCMKTS:ETHE) Jumps On Crypto Hype: Is it Sustainable?

The massive rally in the cryptocurrency space has been one of the biggest stories of the year in investment circles.

Tesoro Enterprises, Inc. (OTCMKTS:TSNP) Turns Volatile in Mid-December

Over the course of the past month, many companies have seen their stocks make substantial gains but the gains made by the...

Over course of the past couple of months, psychedelics-based medicine manufacturer Mind Medicine (MindMed) Inc (OTCMKTS:MMEDF) has seen its stock made massive gains.

Since the middle of September, MMEDF stock has rallied by as much as 400% owing to certain favorable developments and perhaps it’s time for tardy investors to take a closer look at it.

Launch Of Albert

Last Tuesday, the company made another major announcement. Mind Medicine announced the launch of Albert, a new digital division of its business. It is a major development for the company and the news resulted in another strong rally in the stock as well.

Albert is going to be involved in the development of an integrated platform that is going to help in the delivery of psychedelics based medicines. It is a bold move from the company and creates another avenue through which it can sell its products. The platform in question is also going to have a toolset that will further enhance the service provided by the delivery system.

The company believes that the combination of digital solutions with psychedelics based medicines can prove to be a major boon for healthcare professionals. J.R. Rahn, the co-Chief Executive Officer of the company stated that it is the ‘next frontier’ in the psychedelics-based medicines space.

Earlier this month, the company received another boost. Mind Medicine announced that it received approval from the healthcare regulators in Switzerland and the Netherlands with regards to one of its clinical trials.

The approval pertains to the Phase 2A clinical trial to check if ADHD among adults can be treated with microdoses of LSD. It is a step in the right direction for Mind Medicine and the developments are almost certain to be watched closely by investors.

Mind Medicine had earlier reached an agreement with University Hospital Basel Liechti Lab for conducting Phase 2A clinical trial for treating anxiety disorders with LSD.

Latest article

Artificial Intelligence Technology Solutions (OTCMKTS: AITX) Moves Up Quickly On Solid Volume

The artificial intelligence industry has grown at a remarkable pace over the past half a decade or so and over the coming...

Signal Advance Inc (OTCMKTS:SIGL) Makes a Big Move, Again.

Speculation and confusion can often lead to strange occurrences on the stock markets and that is what happened...

Ozop Energy Solutions Inc (OTCMKTS:OZSC) Remains Volatile: Stock in Focus

Those who are looking to discover stocks that may have made big moves over the course of the past week could consider...

Data Storage Corp (OTCMKTS:DTST) Gets Sudden Attention: What’s The Buzz?

One of the stocks to have made significant gains this week was that of Data Storage Corp (OTCMKTS:DTST). The Data Storage Corporation...

A Closer Looks at American Battery Metals Corp (OTCMKTS:ABML) Developments

American Battery Metals Corp (OTCMKTS:ABML) is one of the stocks to have been in focus among investors over the course of the...